Eevia Health

Eevia Health is hosting digital webinars for shareholders, investors, and stakeholders to discuss its strategic reorientation, turnaround plan, rights issue, and funding strategy. The webinars will feature CEO Stein Ulve, CTO Petri Lackman, and Commercial Director Erik Eide. The events are scheduled for February 10 and February 14, 2025. Eevia Health, founded in 2017, focuses on producing bioactive compounds from renewable plant materials for gut and related health areas. The company operates in Finland, producing organic plant extracts for global dietary supplements and food brands. Eevia Health is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.

Under 2024 upplevde Eevia Health PLC en betydande minskning i sina finansiella resultat jämfört med 2023. Ojusterade nettointäkter minskade med 63% till KEUR 1 788, och bruttovinsten sjönk till KEUR 935. EBITDA var negativ med KEUR -345, justerat till KEUR -1 022 efter en engångsvinst från försäljning av tillgångar. Resultatet före skatt blev negativt med KEUR -1 995, främst på grund av lägre intäkter. Personalkostnader minskade till KEUR 1,011 medan overheadkostnader var något lägre. Finansiella kostnader ökade kraftigt till KEUR 574 på grund av dyra brygglån och avgifter under en nyemission. Eevia säkrade nytt kapital genom en nyemission på MEUR 1,5. Lager skrevs ner med KEUR 114, och produkten Retinari™ såldes för KEUR 800, vilket skapade en extraordinär värdeökning av tillgången. Kassaflödet från verksamheten var negativt med KEUR -1 512. Under fjärde kvartalet 2024 var de justerade nettointäkterna KEUR 401. Bruttovinsten minskade till KEUR 148 med en bruttomarginal på 37%. EBITDA var KEUR 257, justerat till KEUR -267. Nettoresultatet för kvartalet var negativt KEUR -118, justerat till KEUR -795. Kassaflödet från verksamheten var positivt med KEUR 4.

In 2024, Eevia experienced a significant decline in financial performance compared to 2023. Net sales decreased by 63% to KEUR 1,788, and the gross profit dropped to KEUR 935. The company's EBITDA was negative at KEUR -345, adjusted to KEUR -1,022 after accounting for a one-time gain from asset sales. The pre-tax result was a loss of KEUR -1,995, primarily due to reduced revenue. Personnel and overhead costs decreased, but financial expenses rose sharply due to costly loans and fees related to a Rights issue that raised MEUR 1.5. Inventory was written down by KEUR 114, and the Retinari™ product was sold for KEUR 800, pending creditor approval. Operating cash flow was negative at KEUR -1,512. In Q4 2024, adjusted net sales were KEUR 401, with a gross profit of KEUR 148 and a gross margin of 37%. EBITDA improved to KEUR 257, including asset sale gains, leading to an adjusted EBITDA of KEUR -267. The net result was KEUR -118, adjusted to KEUR -795 after excluding asset sale gains. Operating cash flow was slightly positive at KEUR 4, influenced by changes in working capital.

An Yhteismetsä, or "Shared Forest," is a Finnish initiative where forest owners can contribute their land in exchange for shares in the venture. These shared forests, which are expanding through new memberships and land purchases, are managed according to forestry plans and certified standards. Eevia Health Oy and Havu Health Oy have partnered with Kauhavan Yhteismetsä to harvest organic-certified pine wood sustainably. This collaboration aims to ensure a high-quality supply chain for wood products and secure new organic certifications. Eevia Health, a company founded in 2017, focuses on producing organic plant extracts for health applications and operates a sustainable production facility in Finland. Eevia is listed on the Spotlight Stock Market in Sweden.

Retinari™ is a compound developed by Eevia Health to prevent Age-related Macular Degeneration (AMD), a leading cause of blindness. Derived from pine wood, the compound has shown promising pre-clinical results but lacks funding for necessary safety studies. Despite strong international interest and accolades, including reaching the finals in the European Innovation Council Accelerator program, Eevia did not secure funding for further development. Consequently, Eevia agreed to sell certain intellectual property rights to Havu Health Oy, a startup founded by Eevia's CTO, for KEUR 800. This transaction includes a fair value assessment and creditor consent, with Eevia receiving shares in Havu Health Oy. Eevia Health, founded in 2017, specializes in sustainable plant extracts for health-related products and operates a green-chemistry facility in Finland.

Eevia's Board of Directors has decided to release the Q4-2024 interim report earlier than planned, moving it from 14 February to 5 February. This change allows insiders to participate in the ongoing rights issue without being restricted by trading bans. Consequently, the subscription period for the rights issue has been extended by one week to give investors more time to consider their options after the report's release. The updated timetable for the rights issue includes specific dates for trading and subscription periods in Sweden and Finland, with the final registration of new shares expected by 3 March. Eevia Health focuses on producing organic plant extracts for global dietary supplements and food brands, operating an environmentally friendly facility in Finland. The press release includes legal and advisory information, emphasizing that it is not an offer to trade securities and highlighting the use of an Exemption Document for the rights issue. It also notes that forward-looking statements are subject to risks and uncertainties.

Retinari™ is a compound developed by Eevia Health to prevent Age-related Macular Degeneration (AMD). It has shown positive pre-clinical results but lacks funding for necessary safety studies to proceed with human testing. Despite high rankings in international funding competitions, Eevia did not secure funding and thus sold certain intellectual property rights to Havu Health Oy for KEUR 800. This sale, subject to fair value assessment and creditor consent, aims to commercialize the product. Eevia will receive shares in Havu Health Oy as payment. Eevia Health, founded in 2017, focuses on bioactive compounds from renewable resources and operates a green-chemistry facility in Finland.

Eevia Health's Board of Directors has decided to release the Q4-2024 interim report earlier than planned, now set for February 4 instead of February 14. This change allows insiders to participate in the ongoing rights issue without being restricted by a trading ban. Consequently, the subscription period for the rights issue has been extended by one week to give investors more time to consider their options after the report's release. The updated subscription timetable includes specific dates for trading and registration in Sweden and Finland. Smartius and Aqurat Fondkommission are providing legal and issuing services, respectively. Eevia Health, established in 2017, is a company focused on producing organic plant extracts for global health products, with a production facility in Finland. The press release clarifies that it is not an offer to trade securities and highlights that the rights issue will only be conducted in Sweden and Finland, with specific legal restrictions in other countries. The release also notes that forward-looking statements are not guarantees of future results and may change.

Eevia Health is hosting a digital webinar for shareholders, investors, and stakeholders to discuss its strategic reorientation, turnaround plan, and rights issue, along with a broader funding strategy. The webinars will be led by CEO Stein Ulve and Chairman Terry Virts, with support from CTO Petri Lackman and Commercial Director Erik Eide. Two sessions are scheduled: February 4 and February 6, 2025, both at 14:00 CET. Registration links are provided, and any issues can be addressed via email. Eevia Health, established in 2017, produces bioactive compounds from sustainably sourced plant materials, focusing on gut and related health areas. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. More information is available on their website and LinkedIn.

Eevia received sales orders totaling KEUR 66 from ten customers, including a new one, with orders primarily for bilberry products and Fenoprolic 70 Organic. Notable orders included KEUR 11 from a French partner and KEUR 8 from a European customer using bilberry extract in animal feed. A Finnish customer ordered KEUR 10 of bilberry products, and Select Ingredients placed an order for a US-based organic brand. A German customer ordered KEUR 10 of Fenoprolic 70 Organic through distributor Breko, and there were US orders for Feno-Chaga Organic and a small order for Feno-Ceraus 5 Organic. A new Latvian customer ordered KEUR 3 of bilberry extract. Most products are in stock, allowing immediate delivery, except for Feno-Ceraus 5, which Eevia can produce quickly. These are repeat orders, and further orders are expected. Eevia Health Plc, founded in 2017, produces organically certified plant extracts for global dietary supplements and food brands, focusing on health areas like gut and kidney health. The company operates a sustainable production facility in Finland and is listed on the Spotlight Stock Market in Sweden.